Carcinogenesis Advance Access originally published online on August 19, 2004
Carcinogenesis 2004 25(12):2379-2384; doi:10.1093/carcin/bgh254
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis vol.25 no.12 © Oxford University Press 2004; all rights reserved.
ARTICLE |
Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma
1 Department of Urology, Yamaguchi University School of Medicine, Yamaguchi, Japan and 2 Department of Clinical Laboratory Science, Yamaguchi University School of Medicine, Yamaguchi, Japan
3 To whom correspondence should be addressed Email: katsunai{at}po.cc.yamaguchi-u.ac.jp
It has been shown that the matrix metalloproteinase (MMP)-1 promoter polymorphism 1G/2G is associated with an increased risk of developing various cancers including renal cell carcinoma (RCC), and is in linkage disequilibrium (LD) with the MMP-3 promoter polymorphism 5A/6A. These two genes are localized in 11q22 adjacent to each other. However, the relationship between the MMP-3 5A/6A polymorphism and susceptibility to cancer remains ambiguous. In this study, we genotyped eight polymorphisms in the region containing the MMP-1 and MMP-3 genes in 177 healthy subjects, and explored the relationships between RCC and these polymorphisms or haplotypes in 156 RCC cases and 230 age- and gender-matched controls. All the subjects studied were of Japanese descent. There were three polymorphisms that showed stronger LD with the MMP-1 1G/2G promoter variant than with the MMP-3 5A/6A promoter variant. One of these three polymorphisms was present in exon 2 of the MMP-3 gene and caused an amino acid change, Glu45Lys (G/A). When the genotype distribution of Glu45Lys was compared between RCC patients and controls, the frequency of the G/G genotype was significantly higher in the patients [age- and gender-adjusted odds ratio (OR) = 1.81, 95% confidence interval (CI) = 1.20–2.74]. A significant increase in the frequency of the 2G/2G genotype of the MMP-1 1G/2G polymorphism was also observed in the patients (age- and gender-adjusted OR = 1.86, CI = 1.23–2.82), whereas there was no significant difference for the MMP-3 5A/6A polymorphism. As expected based on these genotype-level results, the frequency of the 2G-G haplotype of MMP-1 1G/2G and MMP-3 Glu45Lys (G/A) polymorphisms was significantly higher in the patients than in the controls (crude OR = 1.95, CI = 1.31–2.91). These findings suggest that this haplotype of MMP-1 and MMP-3 variants may be associated with the risk of developing RCC.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Peng, L. Cao, W. Wang, L. Xian, D. Jiang, J. Zhao, Z. Zhang, X. Wang, and L. Yu Polymorphisms in the promoter regions of matrix metalloproteinases 1 and 3 and cancer risk: a meta-analysis of 50 case-control studies Mutagenesis, October 20, 2009; (2009) gep041v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Beeghly-Fadiel, Y.-B. Xiang, S. L. Deming, J.-R. Long, W.-H. Xu, Q. Cai, W. Zheng, and X. O. Shu No Association between Matrix Metalloproteinase (MMP)-1, MMP-3, and MMP-7 SNPs and Endometrial Cancer Risk Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1925 - 1928. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Catania, G. Chen, and A. R. Parrish Role of matrix metalloproteinases in renal pathophysiologies Am J Physiol Renal Physiol, March 1, 2007; 292(3): F905 - F911. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Flex, E. Gaetani, A. S. Proia, G. Pecorini, G. Straface, F. Biscetti, G. Fioroni, A. Sabusco, R. Flore, P. Tondi, et al. Analysis of functional polymorphisms of metalloproteinase genes in persons with vascular dementia and Alzheimer's disease. J. Gerontol. A Biol. Sci. Med. Sci., October 1, 2006; 61(10): 1065 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Okayama, Y. Hamanaka, Y. Suehiro, Y. Hasui, J. Nakamura, and Y. Hinoda Association of Interleukin-10 Promoter Single Nucleotide Polymorphisms -819 T/C and -592 A/C With Aging J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2005; 60(12): 1525 - 1529. [Abstract] [Full Text] [PDF]
|
|